Exhibit 99.1
Teladoc Health Reports Third Quarter 2024 Results
PURCHASE, NY, October 30, 2024— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended September 30, 2024 (“Third Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2023 (“Third Quarter 2023”).
Third Quarter 2024 Highlights
•Third Quarter 2024 revenue of $640.5 million, down 3% year-over-year
•Third Quarter 2024 net loss of $33.3 million, or $0.19 per share
•Third Quarter 2024 adjusted EBITDA of $83.3 million, down 6% year-over-year
•Integrated Care segment revenue of $383.7 million, up 2% year-over-year, and adjusted EBITDA margin improved to 17.7%
•BetterHelp segment revenue of $256.8 million, down 10% year-over-year, and adjusted EBITDA margin of 5.9%
“I am pleased with our third quarter results, which demonstrate our commitment to consistent execution, and I remain excited about our potential. I see many strengths to build upon as we advance initiatives aimed at strengthening our business and unlocking future growth opportunities,” said Chuck Divita, Chief Executive Officer of Teladoc Health.
“As we close out 2024, we are moving with urgency and making changes to more effectively leverage our leadership position in the complex and dynamic markets we serve. There is more work ahead of us, and 2025 will be an important repositioning year. Our focus remains on delivering consistent performance and driving long term shareholder value,” Divita added.
| Key Financial Data | |||||||||||||||||||||||||||||||||||
| ($ in thousands, except per share data, unaudited) | |||||||||||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| 2024 | 2023 | Change | 2024 | 2023 | Change | ||||||||||||||||||||||||||||||
| Revenue | $ | 640,508 | $ | 660,238 | (3) | % | $ | 1,929,083 | $ | 1,941,888 | (1) | % | |||||||||||||||||||||||
| Net loss | $ | (33,276) | $ | (57,073) | 42 | % | $ | (952,836) | $ | (191,478) | N/M | ||||||||||||||||||||||||
| Net loss per share, basic and diluted | $ | (0.19) | $ | (0.35) | 46 | % | $ | (5.61) | $ | (1.17) | N/M | ||||||||||||||||||||||||
| Adjusted EBITDA (1) | $ | 83,255 | $ | 88,757 | (6) | % | $ | 235,876 | $ | 213,677 | 10 | % | |||||||||||||||||||||||
See note (1) in the Notes section that follows.
N/M – not meaningful
Third Quarter 2024
Revenue decreased 3% to $640.5 million from $660.2 million in Third Quarter 2023. Access fees revenue decreased 5% to $555.3 million and other revenue grew 9% to $85.2 million. U.S. revenue decreased 6% to $536.2 million and International revenue grew 15% to $104.3 million.
Teladoc Health Integrated Care ("Integrated Care") segment revenue increased 2% to $383.7 million in Third Quarter 2024 and BetterHelp segment revenue decreased 10% to $256.8 million.
1
Net loss totaled $33.3 million, or $0.19 per share, for Third Quarter 2024, compared to $57.1 million, or $0.35 per share, for Third Quarter 2023. Results for Third Quarter 2024 included stock-based compensation expense of $34.0 million, or $0.20 per share pre-tax, and amortization of acquired intangibles of $51.1 million, or $0.30 per share pre-tax. Net loss for Third Quarter 2024 also included $3.6 million, or $0.02 per share pre-tax, of restructuring costs, related to severance costs and costs associated with office space reduction.
Results for Third Quarter 2023 primarily included stock-based compensation expense of $52.9 million, or $0.32 per share pre-tax, and amortization of acquired intangibles of $69.2 million, or $0.42 per share pre-tax.
Adjusted EBITDA(1) decreased 6% to $83.3 million, compared to $88.8 million for Third Quarter 2023. Integrated Care segment adjusted EBITDA increased 8% to $68.0 million in Third Quarter 2024 and BetterHelp segment adjusted EBITDA decreased 41% to $15.2 million in Third Quarter 2024.
GAAP gross margin, which includes amortization of intangible assets and depreciation of property and equipment, was 67.2% for Third Quarter 2024, compared to 68.6% for Third Quarter 2023.
Adjusted gross margin(1) was 71.9% for Third Quarter 2024, compared to 71.8% for Third Quarter 2023.
Nine Months Ended September 30, 2024
Revenue decreased 1% to $1,929.1 million from $1,941.9 million in the first nine months of 2023. Access fees revenue decreased 2% to $1,672.1 million, and other revenue grew 10% to $257.0 million. U.S. revenue decreased 3% to $1,624.6 million, and International revenue grew 13% to $304.5 million for the first nine months of 2024.
Revenue for the Integrated Care segment increased 5% to $1,138.2 million and for the BetterHelp segment decreased 8% to $790.9 million in the first nine months of 2024.
Non-cash goodwill impairment charge of $790.0 million was recorded in the first nine months of 2024 and was attributable to changes in estimates of future cash flows related to the company’s BetterHelp segment. The non-cash charge had no impact on the provision for income taxes.
Net loss totaled $952.8 million, or $5.61 per share, for the first nine months of 2024, compared to
$191.5 million, or $1.17 per share, for the first nine months of 2023. Results for the first nine months of 2024 included a non-cash goodwill impairment charge of $790.0 million, or $4.65 per share pre-tax, stock-based compensation expense of $118.5 million, or $0.70 per share pre-tax, restructuring costs of $14.8 million, or $0.09 per share pre-tax, primarily related to severance costs, and amortization of acquired intangibles of $179.4 million, or $1.06 per share pre-tax.
Results for the first nine months of 2023 primarily included stock-based compensation expense of
$154.7 million, or $0.94 per share pre-tax, and amortization of acquired intangibles of $172.2 million, or $1.05 per share pre-tax. Net loss for the first nine months of 2023 also included $16.0 million, or $0.10 per share pre-tax, of restructuring costs related to the abandonment of certain excess leased office space.
Adjusted EBITDA(1) increased 10% to $235.9 million, compared to $213.7 million for the first nine months of 2023. Integrated Care segment adjusted EBITDA increased 32% to $179.7 million in the first nine months of 2024 and BetterHelp segment adjusted EBITDA decreased 28% to $56.1 million in the first nine months of 2024.
GAAP gross margin, which includes depreciation and amortization, was 66.6% for the first nine months of 2024, compared to 68.0% for the first nine months of 2023.
Adjusted gross margin(1) was 70.8% for the first nine months of 2024 and 2023.
Capex and Cash Flow
Cash flow from operations was $110.2 million in Third Quarter 2024, compared to $105.6 million in Third Quarter 2023, and was $207.8 million in the first nine months of 2024, compared to $219.9 million in the first
2
nine months of 2023. Capitalized expenditures and capitalized software development costs (together, “Capex”) were $31.1 million in Third Quarter 2024, compared to $37.6 million in Third Quarter 2023, and were $94.4 million for the first nine months of 2024, compared to $119.8 million for the first nine months of 2023. Free cash flow was $79.0 million in Third Quarter 2024, compared to $68.0 million in Third Quarter 2023, and was $113.4 million for the first nine months of 2024, compared to $100.1 million for the first nine months of 2023.
Financial Outlook
The outlook provided for the Integrated Care segment is based on current market conditions and expectations and what we know today. Accordingly, we believe our outlook ranges provide a reasonable baseline for future financial performance.
Integrated Care
| For the fourth quarter of 2024, we expect | |||||
| Revenue growth percentage (year-over-year) | 0% - 2.5% | ||||
| Adjusted EBITDA margin | 12.25% - 13.75% | ||||
| U.S. Integrated Care Members (2) | 93.5 - 94.5 million | ||||
| For the full year of 2024, we expect | |||||
| Revenue growth percentage (year-over-year) | Low single digits to mid-single digits | ||||
| Adjusted EBITDA margin | 14.9% - 15.3% | ||||
| U.S. Integrated Care Members (2) | 93.5 - 94.5 million | ||||
Earnings Conference Call
The Third Quarter 2024 earnings conference call and webcast will be held Wednesday, October 30, 2024 at 4:30 p.m. E.T. The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code #781291. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=72270. A live audio webcast will also be available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future financial or operating results, future numbers of members, BetterHelp paying users or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
3
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings, including our ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets; and (viii) the success of our operational review of the company to achieve a more balanced approach to growth and margin. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
4
TELADOC HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data, unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Revenue | $ | 640,508 | $ | 660,238 | $ | 1,929,083 | $ | 1,941,888 | |||||||||||||||
| Costs and expenses: | |||||||||||||||||||||||
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | 179,745 | 185,960 | 562,342 | 566,607 | |||||||||||||||||||
| Advertising and marketing | 177,462 | 186,152 | 531,061 | 541,698 | |||||||||||||||||||
| Sales | 47,465 | 52,309 | 152,267 | 160,329 | |||||||||||||||||||
| Technology and development | 72,383 | 84,289 | 230,522 | 258,583 | |||||||||||||||||||
| General and administrative | 114,245 | 115,716 | 335,494 | 355,702 | |||||||||||||||||||
| Goodwill impairment | — | — | 790,000 | — | |||||||||||||||||||
| Acquisition, integration, and transformation costs | 457 | 5,824 | 1,287 | 16,848 | |||||||||||||||||||
| Restructuring costs | 3,580 | 411 | 14,753 | 16,043 | |||||||||||||||||||
| Amortization of intangible assets | 86,906 | 91,834 | 276,825 | 231,205 | |||||||||||||||||||
| Depreciation of property and equipment | 2,666 | 2,468 | 7,203 | 8,345 | |||||||||||||||||||
| Total costs and expenses | 684,909 | 724,963 | 2,901,754 | 2,155,360 | |||||||||||||||||||
| Loss from operations | (44,401) | (64,725) | (972,671) | (213,472) | |||||||||||||||||||
| Interest income | (15,326) | (12,606) | (42,840) | (33,075) | |||||||||||||||||||
| Interest expense | 5,660 | 5,646 | 16,957 | 16,744 | |||||||||||||||||||
| Other (income) expense, net | (2,239) | 1,792 | (1,306) | (2,908) | |||||||||||||||||||
| Loss before provision for income taxes | (32,496) | (59,557) | (945,482) | (194,233) | |||||||||||||||||||
| Provision for income taxes | 780 | (2,484) | 7,354 | (2,755) | |||||||||||||||||||
| Net loss | $ | (33,276) | $ | (57,073) | $ | (952,836) | $ | (191,478) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.19) | $ | (0.35) | $ | (5.61) | $ | (1.17) | |||||||||||||||
| Weighted-average shares used to compute basic and diluted net loss per share | 171,496,282 | 165,119,379 | 169,824,993 | 164,079,194 | |||||||||||||||||||
Stock-based Compensation Summary
Compensation expense for stock-based awards were classified as follows (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately) | $ | 1,075 | $ | 1,464 | $ | 3,782 | $ | 4,060 | |||||||||||||||
| Advertising and marketing | 3,856 | 4,399 | 11,023 | 11,527 | |||||||||||||||||||
| Sales | 5,204 | 9,110 | 20,124 | 27,055 | |||||||||||||||||||
| Technology and development | 8,152 | 14,566 | 27,134 | 42,984 | |||||||||||||||||||
| General and administrative | 15,760 | 23,406 | 56,416 | 69,082 | |||||||||||||||||||
| Total stock-based compensation expense (3) | $ | 34,047 | $ | 52,945 | $ | 118,479 | $ | 154,708 | |||||||||||||||
See note (3) in the Notes section that follows.
5
Revenues
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| ($ in thousands, unaudited) | 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||||||||||||||||||||||||
| Revenue by Type | |||||||||||||||||||||||||||||||||||
| Access fees | $ | 555,275 | $ | 582,070 | (5) | % | $ | 1,672,097 | $ | 1,708,601 | (2) | % | |||||||||||||||||||||||
| Other | 85,233 | 78,168 | 9 | % | 256,986 | 233,287 | 10 | % | |||||||||||||||||||||||||||
| Total Revenue | $ | 640,508 | $ | 660,238 | (3) | % | $ | 1,929,083 | $ | 1,941,888 | (1) | % | |||||||||||||||||||||||
| Revenue by Geography | |||||||||||||||||||||||||||||||||||
| U.S. Revenue | $ | 536,161 | $ | 569,322 | (6) | % | $ | 1,624,563 | $ | 1,672,770 | (3) | % | |||||||||||||||||||||||
| International Revenue | 104,347 | 90,916 | 15 | % | 304,520 | 269,118 | 13 | % | |||||||||||||||||||||||||||
| Total Revenue | $ | 640,508 | $ | 660,238 | (3) | % | $ | 1,929,083 | $ | 1,941,888 | (1) | % | |||||||||||||||||||||||
Summary Operating Metrics
Consolidated
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| (In millions) | 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||||||||||||||||||||||||
| Total Visits | 4.1 | 4.4 | (7) | % | 12.9 | 14.0 | (8) | % | |||||||||||||||||||||||||||
Integrated Care
| As of September 30, | |||||||||||||||||
| (In millions) | 2024 | 2023 | Change | ||||||||||||||
| U.S. Integrated Care Members (2) | 93.9 | 90.2 | 4 | % | |||||||||||||
| Chronic Care Program Enrollment (4) | 1.179 | 1.122 | 5 | % | |||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| 2024 | 2023 | Change | 2024 | 2023 | Change | ||||||||||||||||||||||||||||||
| Average Monthly Revenue Per U.S. Integrated Care Member (5) | $ | 1.36 | $ | 1.41 | (4) | % | $ | 1.37 | $ | 1.40 | (2) | % | |||||||||||||||||||||||
BetterHelp
| Average for | Average for | ||||||||||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| (In millions) | 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||||||||||||||||||||||||
| BetterHelp Paying Users (6) | 0.398 | 0.459 | (13) | % | 0.407 | 0.467 | (13) | % | |||||||||||||||||||||||||||
See notes (2), (4), (5), and (6) in the Notes section that follows.
6
Operating Results by Segment (see note (7) in the Notes section that follows)
The following table presents operating results by reportable segment for the periods indicated:
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| ($ in thousands, unaudited) | 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||||||||||||||||||||||||
| Teladoc Health Integrated Care | |||||||||||||||||||||||||||||||||||
| Revenue | $ | 383,666 | $ | 374,416 | 2 | % | $ | 1,138,198 | $ | 1,084,438 | 5 | % | |||||||||||||||||||||||
| Adjusted EBITDA | $ | 68,039 | $ | 62,805 | 8 | % | $ | 179,741 | $ | 135,900 | 32 | % | |||||||||||||||||||||||
| Adjusted EBITDA Margin % | 17.7 | % | 16.8 | % | 15.8 | % | 12.5 | % | |||||||||||||||||||||||||||
| BetterHelp | |||||||||||||||||||||||||||||||||||
| Therapy Services | $ | 250,588 | $ | 281,204 | (11) | % | $ | 773,373 | $ | 845,420 | (9) | % | |||||||||||||||||||||||
| Other Wellness Services | 6,254 | 4,618 | 35 | % | 17,512 | 12,030 | 46 | % | |||||||||||||||||||||||||||
| Total Revenue | $ | 256,842 | $ | 285,822 | (10) | % | $ | 790,885 | $ | 857,450 | (8) | % | |||||||||||||||||||||||
| Adjusted EBITDA | $ | 15,216 | $ | 25,952 | (41) | % | $ | 56,135 | $ | 77,777 | (28) | % | |||||||||||||||||||||||
| Adjusted EBITDA Margin % | 5.9 | % | 9.1 | % | 7.1 | % | 9.1 | % | |||||||||||||||||||||||||||
7
TELADOC HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
| Nine Months Ended September 30, | |||||||||||
| 2024 | 2023 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | (952,836) | $ | (191,478) | |||||||
| Adjustments to reconcile net loss to net cash flows from operating activities: | |||||||||||
| Goodwill impairment | 790,000 | — | |||||||||
| Amortization of intangible assets | 276,825 | 231,205 | |||||||||
| Depreciation of property and equipment | 7,203 | 8,345 | |||||||||
| Amortization of right-of-use assets | 7,144 | 8,325 | |||||||||
| Provision for allowances for doubtful accounts | 2,199 | 4,935 | |||||||||
| Stock-based compensation | 118,479 | 154,727 | |||||||||
| Deferred income taxes | 611 | (6,658) | |||||||||
| Other, net | 5,212 | 9,761 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | 3,675 | (696) | |||||||||
| Prepaid expenses and other current assets | 2,849 | 14,070 | |||||||||
| Inventory | (8,328) | 18,246 | |||||||||
| Other assets | 1,439 | (18,362) | |||||||||
| Accounts payable | (5,851) | (21,670) | |||||||||
| Accrued expenses and other current liabilities | 13,980 | 17,075 | |||||||||
| Accrued compensation | (35,943) | 433 | |||||||||
| Deferred revenue | (10,456) | (1,261) | |||||||||
| Operating lease liabilities | (8,088) | (7,133) | |||||||||
| Other liabilities | (336) | 75 | |||||||||
| Net cash provided by operating activities | 207,778 | 219,939 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Capital expenditures | (4,658) | (10,060) | |||||||||
| Capitalized software development costs | (89,750) | (109,781) | |||||||||
| Net cash used in investing activities | (94,408) | (119,841) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Net proceeds from the exercise of stock options | 2,711 | 1,423 | |||||||||
| Proceeds from employee stock purchase plan | 3,721 | 8,597 | |||||||||
| Cash received for withholding taxes on stock-based compensation, net | (176) | 2,609 | |||||||||
| Other, net | (2) | — | |||||||||
| Net cash provided by financing activities | 6,254 | 12,629 | |||||||||
| Net increase in cash and cash equivalents | 119,624 | 112,727 | |||||||||
| Effect of foreign currency exchange rate changes | 567 | (382) | |||||||||
| Cash and cash equivalents at beginning of the period | 1,123,675 | 918,182 | |||||||||
| Cash and cash equivalents at end of the period | $ | 1,243,866 | $ | 1,030,527 | |||||||
8
The following table presents the selected cash flow information for the following quarters (in thousands, unaudited):
| Three Months Ended September 30, | |||||||||||
| 2024 | 2023 | ||||||||||
| Net cash provided by operating activities | $ | 110,175 | $ | 105,601 | |||||||
| Net cash used in investing activities | (31,148) | (37,647) | |||||||||
| Net cash provided by financing activities | 698 | 5,068 | |||||||||
| Effect of foreign currency exchange rate changes | 1,758 | (1,190) | |||||||||
| Net increase in cash and cash equivalents | $ | 81,483 | $ | 71,832 | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data, unaudited)
| September 30, 2024 | December 31, 2023 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 1,243,866 | $ | 1,123,675 | |||||||
| Accounts receivable, net of allowance for doubtful accounts of $4,318 and $4,240 at September 30, 2024 and December 31, 2023, respectively | 212,039 | 217,423 | |||||||||
| Inventories | 36,993 | 29,513 | |||||||||
| Prepaid expenses and other current assets | 115,738 | 118,437 | |||||||||
| Total current assets | 1,608,636 | 1,489,048 | |||||||||
| Property and equipment, net | 28,030 | 32,032 | |||||||||
| Goodwill | 283,190 | 1,073,190 | |||||||||
| Intangible assets, net | 1,496,698 | 1,677,781 | |||||||||
| Operating lease—right-of-use assets | 34,115 | 40,060 | |||||||||
| Other assets | 77,912 | 80,258 | |||||||||
| Total assets | $ | 3,528,581 | $ | 4,392,369 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 37,801 | $ | 43,637 | |||||||
| Accrued expenses and other current liabilities | 188,095 | 178,634 | |||||||||
| Accrued compensation | 66,437 | 102,686 | |||||||||
| Deferred revenue—current | 88,325 | 95,659 | |||||||||
| Convertible senior notes, net—current | 550,723 | — | |||||||||
| Total current liabilities | 931,381 | 420,616 | |||||||||
| Other liabilities | 736 | 1,080 | |||||||||
| Operating lease liabilities, net of current portion | 36,896 | 42,837 | |||||||||
| Deferred revenue, net of current portion | 10,469 | 13,623 | |||||||||
| Deferred taxes, net | 50,846 | 49,452 | |||||||||
| Convertible senior notes, net—non-current | 990,551 | 1,538,688 | |||||||||
| Total liabilities | 2,020,879 | 2,066,296 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Common stock, $0.001 par value; 300,000,000 shares authorized; 171,944,014 shares and 166,658,253 shares issued and outstanding as of September 30, 2024 and December 31, 2023 respectively | 172 | 167 | |||||||||
| Additional paid-in capital | 17,726,127 | 17,591,551 | |||||||||
| Accumulated deficit | (16,181,491) | (15,228,655) | |||||||||
| Accumulated other comprehensive loss | (37,106) | (36,990) | |||||||||
| Total stockholders’ equity | 1,507,702 | 2,326,073 | |||||||||
| Total liabilities and stockholders’ equity | $ | 3,528,581 | $ | 4,392,369 | |||||||
9
Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we use certain non-GAAP financial measures to clarify and enhance an understanding of past performance, which include adjusted gross profit, adjusted gross margin, adjusted EBITDA, and free cash flow. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance, and are commonly used by investors to evaluate our performance and that of our competitors. We further believe that these financial measures are useful to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows. We use these non-GAAP financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as a key measure of our performance.
Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which are shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue.
Adjusted EBITDA consists of net loss before provision for income taxes; other (income) expense, net; interest income; interest expense; depreciation of property and equipment; amortization of intangible assets; restructuring costs; acquisition, integration, and transformation cost; goodwill impairment; and stock-based compensation.
Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.
Our use of these non-GAAP terms may vary from that of others in our industry, and other companies may calculate such measures differently than we do, limiting their usefulness as comparative measures.
Non-GAAP measures have important limitations as analytical tools and you should not consider them in isolation, and they should not be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other measures derived in accordance with GAAP. Some of these limitations are:
•adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our clients, the number of visits and cases we complete, the costs paid to providers and medical experts, as well as the costs of our provider network operations center;
•adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;
•adjusted EBITDA eliminates the impact of the provision for income taxes on our results of operations, and it does not reflect other (income) expense, net, interest income, or interest expense;
•adjusted EBITDA does not reflect restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;
•adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration, and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our customer relationship management (CRM) and enterprise resource planning (ERP) systems. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but, rather, incremental costs incurred in connection with our acquisition and integration activities;
•adjusted EBITDA does not reflect goodwill impairment; and
10
•adjusted EBITDA does not reflect the significant non-cash stock-based compensation expense which should be viewed as a component of recurring operating costs.
In addition, although amortization of intangible assets and depreciation of property and equipment are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, and adjusted EBITDA do not reflect any expenditures for such replacements.
We compensate for these limitations by using these non-GAAP measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.
In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
The following is a reconciliation of gross profit, the most directly comparable GAAP financial measure, to adjusted gross profit:
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit
(In thousands, unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Revenue | $ | 640,508 | $ | 660,238 | $ | 1,929,083 | $ | 1,941,888 | |||||||||||||||
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | (179,745) | (185,960) | (562,342) | (566,607) | |||||||||||||||||||
| Amortization of intangible assets and depreciation of property and equipment | (30,237) | (21,088) | (82,695) | (55,094) | |||||||||||||||||||
| Gross Profit | 430,526 | 453,190 | 1,284,046 | 1,320,187 | |||||||||||||||||||
| Amortization of intangible assets and depreciation of property and equipment | 30,237 | 21,088 | 82,695 | 55,094 | |||||||||||||||||||
| Adjusted gross profit | $ | 460,763 | $ | 474,278 | $ | 1,366,741 | $ | 1,375,281 | |||||||||||||||
| Gross margin | 67.2 | % | 68.6 | % | 66.6 | % | 68.0 | % | |||||||||||||||
| Adjusted gross margin | 71.9 | % | 71.8 | % | 70.8 | % | 70.8 | % | |||||||||||||||
11
The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to adjusted EBITDA:
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(In thousands, unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||||||||||||
| Net loss | $ | (33,276) | $ | (57,073) | $ | (952,836) | $ | (191,478) | |||||||||||||||||||||||||||
| Add: | |||||||||||||||||||||||||||||||||||
| Provision for income taxes | 780 | (2,484) | 7,354 | (2,755) | |||||||||||||||||||||||||||||||
| Other (income) expense, net | (2,239) | 1,792 | (1,306) | (2,908) | |||||||||||||||||||||||||||||||
| Interest expense | 5,660 | 5,646 | 16,957 | 16,744 | |||||||||||||||||||||||||||||||
| Interest income | (15,326) | (12,606) | (42,840) | (33,075) | |||||||||||||||||||||||||||||||
| Depreciation of property and equipment | 2,666 | 2,468 | 7,203 | 8,345 | |||||||||||||||||||||||||||||||
| Amortization of intangible assets | 86,906 | 91,834 | 276,825 | 231,205 | |||||||||||||||||||||||||||||||
| Restructuring costs | 3,580 | 411 | 14,753 | 16,043 | |||||||||||||||||||||||||||||||
| Acquisition, integration, and transformation costs | 457 | 5,824 | 1,287 | 16,848 | |||||||||||||||||||||||||||||||
| Goodwill impairment | — | — | 790,000 | — | |||||||||||||||||||||||||||||||
| Stock-based compensation | 34,047 | 52,945 | 118,479 | 154,708 | |||||||||||||||||||||||||||||||
| Total Adjustments | 38,084 | 59,180 | 924,519 | 187,599 | |||||||||||||||||||||||||||||||
| Consolidated Adjusted EBITDA | $ | 83,255 | $ | 88,757 | $ | 235,876 | $ | 213,677 | |||||||||||||||||||||||||||
| Segment Adjusted EBITDA | |||||||||||||||||||||||||||||||||||
| Teladoc Health Integrated Care | $ | 68,039 | $ | 62,805 | $ | 179,741 | $ | 135,900 | |||||||||||||||||||||||||||
| BetterHelp | 15,216 | 25,952 | 56,135 | 77,777 | |||||||||||||||||||||||||||||||
| Consolidated Adjusted EBITDA | $ | 83,255 | $ | 88,757 | $ | 235,876 | $ | 213,677 | |||||||||||||||||||||||||||
The following is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP financial measure, to free cash flow:
Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow
(In thousands, unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||||||
| Net cash provided by operating activities | $ | 110,175 | $ | 105,601 | $ | 207,778 | $ | 219,939 | |||||||||||||||||||||
| Capital expenditures | (1,597) | (5,793) | (4,658) | (10,060) | |||||||||||||||||||||||||
| Capitalized software development costs | (29,551) | (31,854) | (89,750) | (109,781) | |||||||||||||||||||||||||
| Capex | (31,148) | (37,647) | (94,408) | (119,841) | |||||||||||||||||||||||||
| Free Cash Flow | $ | 79,027 | $ | 67,954 | $ | 113,370 | $ | 100,098 | |||||||||||||||||||||
Notes:
1.A reconciliation of each non-GAAP measure to the most comparable measure under GAAP has been provided in this press release in the accompanying tables. An explanation of these non-GAAP measures is also included under the heading “Non-GAAP Financial Measures.”
2.U.S. Integrated Care Members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.
3.Excluding the amount capitalized related to software development projects.
12
4.Chronic Care Program Enrollment represents the total number of enrollees across our suite of chronic care programs at the end of the applicable period.
5.Average monthly revenue per U.S. Integrated Care member is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care Members (see note 2) during the applicable period.
6.BetterHelp Paying Users represent the average number of global monthly paying users of our BetterHelp therapy services during the applicable period.
7.We have two segments: Teladoc Health Integrated Care (“Integrated Care”) and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis.
Investors:
Michael Minchak
617-444-9612
ir@teladochealth.com
Media:
Chris Stenrud
860-491-8821
pr@teladochealth.com
13